About us
Why We Exist
Our Mission
The Oxalosis & Hyperoxaluria Foundation (OHF) is dedicated to finding treatments and a cure for all forms of hyperoxaluria.
Our Impact
We support thousands of healthcare professionals, patients, and their families, and we aim to share our knowledge so that everyone has accurate information about the advances in this disease.
By supporting research and spreading awareness about the disease among patients, medical professionals, government officials, the general public, and industry, we aspire to create brighter tomorrows for those impacted by primary hyperoxaluria, oxalosis, and related hyperoxaluria kidney stone conditions.
How We Do It
We are a donor-funded, 501(c)(3) nonprofit, spending 90% of every dollar raised on research and programs for our community.
Executive Leadership
Our people are determined and innovative, working around the clock to end hyperoxaluria. The contributions from these exceptional individuals keep the Oxalosis & Hyperoxaluria Foundation moving forward.
Meet the Staff
Kim Hollander
Executive Director, New York, New York
Julie Bertarelli
Operations Coordinator, St. Louis, Missouri
Board of Directors
Our voluntary Board of Directors provides oversight and governance. Directors represent a variety of professional backgrounds with one thing in common: They all have been touched by hyperoxaluria and its complications.
Meet the Board Members
Brett Rosen
Chair
New York, New York
Brendan McGovern
President
New Hyde Park, New York
Tim Berra
Vice President
St. Louis, Missouri
Don Ashkenase
Treasurer
Great Neck, New York
Lisa Berra
Secretary
St. Louis, Missouri
William C. Tidmore, Jr. MD
Director
Valdosta, Georgia
Debra Wattenberg MD
VP of Science & Medical Affairs
New York, New York
Scientific Advisory Board and Scientific Advisory Council
The Scientific Advisory Board and Scientific Advisory Council are rotating committees of thought leaders who act as external advisors. They provide guidance and direction on our overall research strategy.
Meet the Scientific Advisory Board
John C. Lieske MD
Chair
Mayo Clinic
Rochester, Minnesota
David Goldfarb MD
NYU Langone Medical Center
New York, New York
W. Todd Lowther PhD
Vice Chair
Wake Forest School of Medicine
Winston-Salem, North Carolina
Yaacov Frishberg MD
Shaare Zedek Medical Center
Jerusalem, Israel
Michelle Baum MD
Boston Children’s Hospital
Boston, Massachusetts
Felix Knauf MD
Charité – University Medicine Berlin
Berlin, Germany
Bodo Beck MD
University of Cologne
Cologne, Germany
Angel Pey, PhD
University of Granada
Granada, Spain
Carla Koehler, PhD
USCL
Los Angeles, California
Eduardo Salido MD, PhD
Hospital Universitario Canaria, University La Laguna
Tenerife, Spain
Scientific Advisory Council
The Scientific Advisory Council (SAC), comprising specialists and experts in related fields, provides independent advice as needed to the Scientific Advisory Board (SAB) on matters of concern in primary hyperoxaluria. The SAC may also review the foundation’s research portfolio and identify promising new areas of research.
Meet the Scientific Advisory Council
John Asplin MD
Litholink Corporation
Chicago, Illinois
Amy Krambeck PhD
Mayo Clinic
Rochester, Minnesota
Dean G. Assimos MD
University of Alabama
School of Medicine
Birmingham, Alabama
Kay Latta MD
Clementine-Kinderhospital
Frankfurt, Germany
Ruth Belostotsky PhD
Shaare Zedek Medical Center
Jerusalem, Israel
Naim Maalouf MD
University of Texas Southwestern Medical Center
Dallas, Texas
Nicola Brunetti-Pierri MD
University of Naples
Naples, Italy
Robert B. Miller MD
Presbyterian Hospital
Albuquerque, New Mexico
Benjamin K. Canales MD, MPH
University of Florida
Gainesville, Florida
Dawn Milliner MD
Mayo Clinic
Rochester, Minnesota
Pierre Cochat MD
Hôpital Femme Mère Enfant
Université Lyon
Lyon, France
Helen O’Connor MS, RD, CCRP
Mayo Clinic
Rochester, Minnesota
Scott Cramer PhD
University of Colorado
Aurora, Colorado
Elisa Oppici PhD
University of Verona
Verona, Italy
Christopher Danpure PhD
University College London
London, United Kingdom
Angel Pey PhD
University of Granada
Granada, Spain
Mario De Marchi MD
University of Torino
Torino, Italy
Edward Purdue PhD
Mount Sinai School of Medicine
New York, New York
Monica Diaz-Gavilan PhD
University of Granada
Granada, Spain
Michael Romero PhD
Mayo Clinic
Rochester, Minnesota
Sonia Fargue PhD
University of Alabama
Birmingham, Alabama
Jayanta Roy-Chowdhury MD
Albert Einstein College of Medicine
Bronx, New York
Jaap Groothof MD
Emma Children’s Hospital
Amsterdam, Netherlands
Namita Roy-Chowdhury PhD
Albert Einstein College of Medicine
Bronx, New York
Hatim Hassan MD
University of Chicago
Chicago, Illinois
Gill Rumsby PhD, FRC
University College London
London, United Kingdom
Marguerite Hatch PhD
University of Florida
Gainesville, Florida
Eduardo Salido MD, PhD
University Laguna
Tenerife, Spain
John Herrin MD
Children’s Hospital Boston
Boston, Massachusetts
Jose Sanchez-Ruiz
University of Granada
Granada, Spain
Ross Holmes PhD
University of Alabama
School of Medicine
Birmingham, Alabama
Davis Sas DO
Mayo Clinic
Rochester, Minnesota
Markus J. Kemper
Universitäts-Klinikum Hamburg Eppendorf
Hamburg, Germany
Chandra Tucker PhD
University of Colorado
Aurora, Colorado
Saeed Khan PhD
University of Florida
Gainesville, Florida
Carla Voltattorni PhD
University of Verona
Verona, Italy
Robert Kleta MD
Royal Free Hospital
London, United Kingdom
Emma Walker PhD
University College London
London, England
Hari K Koul MSc, PhD, FACN, FASN
LSU Health Shreveport
Shreveport, Louisiana
Elaine Worcester MD
University of Chicago
Chicago, IL
Statements
The Oxalosis & Hyperoxaluria Foundation is a non-profit 501(c)(3) organization, and all donations are tax deductible.